Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis
1Centre for Rheumatic Diseases, University of Glasgow, Glasgow, United Kingdom.
Insights
Chronic inflammation increases cardiovascular risk in inflammatory joint diseases like rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Treatments targeting inflammation may reduce these risks.
Area of Science:
- Rheumatology
- Immunology
- Cardiology
Background:
- Chronic inflammation is linked to cardiovascular complications, including hypertension, stroke, and myocardial infarction.
- Inflammatory joint diseases like rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with dyslipidemia, elevated C-reactive protein (CRP), and interleukin-6 (IL-6) levels.
- RA patients exhibit increased mortality, primarily due to cardiovascular disease, while AS patients show a lesser, but still significant, cardiovascular morbidity.
Purpose of the Study:
- To explore the relationship between chronic inflammation, cardiovascular co-morbidity, and inflammatory joint diseases.
- To investigate the impact of dyslipidemia and acute phase response markers on cardiovascular risk in RA and AS.
- To examine the potential of anti-tumour necrosis factor-alpha (TNF-alpha) therapies in mitigating cardiovascular complications.
Main Methods:
- Review of existing literature on cardiovascular complications in inflammatory joint diseases.
- Analysis of the association between inflammatory markers (CRP, IL-6) and lipid profiles.
- Evaluation of studies investigating the effects of anti-TNF-alpha therapy on cardiovascular outcomes.
Main Results:
- An elevated acute phase response is a predisposing factor for hypertension, stroke, and myocardial infarction.
- Dyslipidemia is a characteristic feature of inflammatory joint diseases, correlating with elevated CRP and IL-6.
- Therapeutic agents like anti-TNF-alpha drugs may reduce cardiovascular complications in RA and AS by down-regulating the acute phase response.
Conclusions:
- Cardiovascular co-morbidity is a significant concern in chronic inflammatory conditions, particularly RA and AS.
- Management of inflammation and associated dyslipidemia is crucial for reducing cardiovascular risk.
- Targeting inflammatory pathways with agents like anti-TNF-alpha shows promise in preventing cardiovascular events in these patient populations.
Abstract:
Cardiovascular co-morbidity is now a recognised complication of chronic inflammation and an elevated acute phase response predisposes to hypertension, stroke and myocardial infarction. Dyslipidaemia is a feature of inflammatory joint diseases and is closely related to elevated CRP and Il-6 levels. Rheumatoid arthritis (RA) has an increased standardised mortality ratio largely attributable to cardiovascular risk. An increased although lesser, cardiovascular morbidity has also been observed in ankylosing spondylitis (AS) which has a similar abnormal lipid profile to that seen in RA. There is some evidence that therapeutic agents such as anti-tumour necrosis factor-alpha (TNF-alpha) drugs that down-regulate the acute phase response, also have an effect in reducing cardiovascular complications in RA and AS.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease IV: Nursing Management
Coronary Artery Disease I: Introduction

